Related Experiment Videos
The effects of converting from simvastatin to atorvastatin on plasminogen activator inhibitor type-1
1University of the Pacific School of Pharmacy, Stockton, USA.
Insights
Switching from simvastatin to atorvastatin does not significantly alter plasminogen activator inhibitor type-1 (PAI-1) levels in patients with coronary artery disease (CAD). This study found no adverse effects on PAI-1 concentrations after the medication conversion.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Plasminogen activator inhibitor type-1 (PAI-1) is a key regulator of fibrinolysis, often elevated in endothelial dysfunction.
- Elevated PAI-1 and endothelial dysfunction in coronary artery disease (CAD) patients can improve with simvastatin therapy.
- The impact of switching from simvastatin to atorvastatin on PAI-1 levels remains uninvestigated.
Purpose of the Study:
- To evaluate the effect of converting from simvastatin to atorvastatin on plasma PAI-1 concentrations in patients with CAD.
- To determine if switching statin medication impacts PAI-1 levels, a marker of endothelial dysfunction.
Main Methods:
- A randomized study involving 14 adult patients with hypercholesterolemia and CAD.
- Patients on simvastatin were randomized to continue or switch to atorvastatin, with doses adjusted for LDL cholesterol < or = 100 mg/dL.
- Fasting lipid panels and PAI-1 levels were measured at baseline and after 10 weeks.
Main Results:
- No significant differences in LDL cholesterol levels were observed between the simvastatin and atorvastatin groups at baseline or after 10 weeks.
- Plasma PAI-1 concentrations showed no significant differences at baseline or after 10 weeks between the two treatment groups.
- Mean PAI-1 levels at 10 weeks were 51.1 +/- 32.5 ng/mL for simvastatin and 63.9 +/- 26.9 ng/mL for atorvastatin (p = 0.44).
Conclusions:
- Conversion from simvastatin to atorvastatin does not appear to adversely affect PAI-1 plasma concentrations in patients with CAD.
- This finding suggests that statin medication switches may be made without concern for negative impacts on PAI-1 levels.
- Further research could explore long-term effects and broader cardiovascular implications.
Abstract:
Plasminogen activator inhibitor type-1 (PAI-1) is an important regulatory component of fibrinolysis and is elevated in the presence of endothelial dysfunction. Endothelial dysfunction and PAI-1 in patients with coronary artery disease (CAD) have been demonstrated to improve following simvastatin therapy. The effect of converting from simvastatin to atorvastatin on PAI-1 has not been reported and may be an additional consideration when making a formulary medication switch. Fourteen adult patients with hypercholesterolemia and CAD who were receiving simvastatin for a minimum of 3 months were randomized to continue on simvastatin or be converted to atorvastatin. Doses were adjusted to achieve or sustain a low-density lipoprotein (LDL) cholesterol of < or = 100 mg/dL. A fasting lipid panel and PAI-1 were obtained at baseline and following 10 weeks of treatment. Mean +/- SD LDL cholesterol at baseline (95.6 +/- 13.8 vs. 87.0 +/- 12.3 dL, p = 0.24) and following 10 weeks of simvastatin or atorvastatin (96.6 +/- 8.9 vs. 87.4 +/- 20.3 mg/dL, p = 0.29) were similar. No differences in PAI-1 were observed at baseline (47.7 +/- 19.3 vs. 64.6 +/- 22.2 ng/mL, p = 0.15) or at 10 weeks (51.1 +/- 32.5 vs. 63.9 +/- 26.9 ng/mL, p = 0.44). These data suggest that the conversion from simvastatin to atorvastatin does not adversely affect PAI-1 plasma concentrations in patients with CAD.